Table 1.
Patient Demographics by Randomized Treatment Group
| Variable | ATX + PT n=32 |
ATX n=32 |
Placebo + PT n=32 |
Placebo n=32 |
p Value Comparing Groups |
|
|---|---|---|---|---|---|---|
| Age, y (%) | 8.0 (1.9) | 8.6 (2.3) | 7.7 (1.5) | 8.2 (2.4) | .29 | |
| IQ, standard score (%) |
83.3 (21.6) | 78.7 (25.9) | 77.9 (25.7) | 86.7 (23.7) | .43 | |
| Autistic Disorder, % | 37.5 | 43.8 | 43.8 | 53.1 | .70 | |
| Asperger’s, % | 15.6 | 21.9 | 15.6 | 12.5 | .84 | |
| PDD-NOS, % | 46.9 | 34.4 | 40.6 | 34.3 | .73 | |
| Male, % | 96.9 | 81.3 | 84.4 | 78.1 | .13 | |
| Caucasian, % | 87.5 | 84.4 | 81.3 | 75.0 | .67 | |
| African Am, % | 3.1 | 6.3 | 6.3 | 15.6 | .39 | |
| Income ≥$60K (%) | 56.3 | 46.9 | 53.1 | 56.3 | .91 | |
| <$60K | 43.7 | 53.1 | 46.9 | 43.7 | ||
| Regular Ed, % | 43.7 | 28.1 | 46.9 | 65.6 | .028 | |
| Special Ed, % | 56.3 | 71.9 | 53.1 | 34.4 | ||
| ADHD CGI-S, n (%) | ||||||
| Moderate | 9 (28) | 9 (28) | 7 (22)a | 9 (28) | .44 | |
| Marked | 19 (59) | 15 (47) | 18 (58)a | 12 (38) | ||
| Severe/Extreme | 4 (13) | 8 (25) | 6 (19) | 11 (34) | ||
| Non-Compliance CGI-S, n (%) | ||||||
| Mild | 2 (6) | 1 (3) | 1 (3)a | 1 (3) | .90 | |
| Moderate | 19 (59) | 16 (50) | 17 (53)a | 15 (47) | ||
| Marked/Severe | 11 (35) | 15 (47) | 13 (41)a | 16 (50) | ||
Note: ADHD = attention-deficit/hyperactivity disorder; ATX = atomoxetine; CGI-S = Clinical Global Impressions-Severity score; PDD-NOS = pervasive developmental disorder-not otherwise specified; PT = parent training.
a
One participant’s data not obtained.